"Recombinant human lysozyme" or alternative to antibiotics

The industry believes that "recombinant human lysozyme" is a green, environmentally friendly, and ecological new product.

With the support of a number of major special scientific research funds such as the National "863", "Tenth Five-Year Plan" and "Eleventh Five-Year Plan", the Qilong Biotechnology R&D team lasted 15 years, independently innovated and arduous research, and fully mastered the genetically recombinant human lysozyme.

The scientific research team used advanced yeast secretory eukaryotic cells, genetic recombination bioengineering technology, and process innovation to successfully produce human-derived "recombinant human lysozyme" with high expression, high activity and purity of over 99.

According to reports, lysozyme is a non-specific immune factor possessed by almost all organisms in the world.

The current clinical use of lysozyme is mainly egg white lysozyme.

At present, the world's top scientific research institutions are using genetic recombination technology to realize the research and development of human lysozyme

In December 2020, the Wuhan Institute of Virology of the Chinese Academy of Sciences and the scientific research team of Guangzhou Qilong Biotechnology Co.

On April 29 this year, an experimental report from the National African Swine Fever Professional Laboratory of the Harbin Veterinary Research Institute of the Chinese Academy of Agricultural Sciences showed that the use of "recombinant human lysozyme" to inactivate the African swine fever virus has an inhibition rate of 5000 The unit and 10,000 unit concentrations are 83.

Experts in the industry pointed out that "recombinant human lysozyme" is a green, environmentally friendly and ecological new product.

In an interview with reporters, the person in charge of Guangzhou Qilong Biotechnology Co.